Optimal Treatment Duration for MRSA-Related Pneumonia
The national practice guideline for treating MRSA-related pneumonia is seven to 21 days. A Henry Ford Hospital study found that effective treatment can be done in half the time.
Researchers found that 40 percent of patients were treated for eight to 13 days on a therapy of the antibiotics vancomycin or linezolid, and had the highest survival rate.
The Henry Ford study is believed to be the first to evaluate the length of treatment for MRSA-related pneumonia. The study was presented last week at the IDWeek meeting in San Diego.
"Based on our study, clinicians can effectively treat their patients within eight to 13 days, thus minimizing patients' exposure to antibiotics and their side effects," says Hadeel Zainah, MD, a second-year Infectious Diseases fellow at Henry Ford and the study's lead author.
MRSA-related pneumonia is a respiratory illness that typically follows a bout of the flu. Symptoms include a cough, sore throat, head ache, shortness of breath, fever and chills.
In the retrospective study, researchers evaluated the medical charts of 115 patients hospitalized with MRSA pneumonia. Patients received either vancomycin or linezolid, or both.
Of the 115 patients, 32 died after 28 days. Other findings:
- 27 percent of patients were treated for 14-20 days.
- 13.9 percent of patients were treated for more than 20 days.
- These treatment durations had lower survival rates than the eight to 13 days.
Researchers did not evaluate whether the treatment duration affected length of stay or whether one antibiotic fared better than the other.
The study was funded by Henry Ford Hospital.
Building Infection Prevention Capacity in the Middle East: A 7-Year Certification Success Story
June 17th 2025Despite rapid development, the Middle East faces a critical shortage of certified infection preventionists. A 7-year regional initiative has significantly boosted infection control capacity, increasing the number of certified professionals and elevating patient safety standards across health care settings.
Streamlined IFU Access Boosts Infection Control and Staff Efficiency
June 17th 2025A hospital-wide quality improvement project has transformed how staff access critical manufacturer instructions for use (IFUs), improving infection prevention compliance and saving time through a standardized, user-friendly digital system supported by unit-based training and interdepartmental collaboration.
Swift Isolation Protocol Shields Chicago Children’s Hospital During 2024 Measles Surge
June 17th 2025When Chicago logged its first measles cases linked to crowded migrant shelters last spring, one pediatric hospital moved in hours—not days—to prevent the virus from crossing its threshold. Their playbook offers a ready template for the next communicable-disease crisis.
Back to Basics: Hospital Restores Catheter-Associated UTI Rates to Prepandemic Baseline
June 16th 2025A 758-bed quaternary medical center slashed catheter-associated urinary tract infections (CAUTIs) by 45% over 2 years, proving that disciplined adherence to fundamental prevention steps, not expensive add-ons, can reverse the pandemic-era spike in device-related harm.
Global Patients, Local Risks: Why Medical Tourism Demands Infection Preventionists’ Attention
June 16th 2025At APIC25, infection prevention leader Heather Stoltzfus, MPH, RN, CIC, will spotlight the growing risks and overlooked responsibilities associated with medical tourism. Her session urges infection preventionists to engage with a global health trend that directly impacts US care settings.
